Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejandro J Roman

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Human Molecular Genetics|May 9, 2008
Usher syndromes due to MYO7A, PCDH15, USH2A or GPR98 mutations share retinal disease mechanismSamuel G Jacobson, Artur V Cideciyan, Tomas S Aleman, et al.
Investigative Ophthalmology & Visual Science|July 7, 2009
CERKL mutations cause an autosomal recessive cone-rod dystrophy with inner retinopathyTomas S Aleman, Nagasamy Soumittra, Artur V Cideciyan, et al.
Iscience|May 17, 2021
Safety and improved efficacy signals following gene therapy in childhood blindness caused by <i>GUCY2D</i> mutationsSamuel G Jacobson, Artur V Cideciyan, Allen C Ho, et al.
Iscience|October 24, 2022
Night vision restored in days after decades of congenital blindnessSamuel G Jacobson, Artur V Cideciyan, Allen C Ho, et al.
Investigative Ophthalmology & Visual Science|July 16, 2011
Human CRB1-associated retinal degeneration: comparison with the rd8 Crb1-mutant mouse modelTomas S Aleman, Artur V Cideciyan, Geoffrey K Aguirre, et al.
International Journal of Molecular Sciences|October 16, 2024
Evaluation of Retinal Structure and Visual Function in Blue Cone Monochromacy to Develop Clinical Endpoints for L-opsin Gene TherapyArtur V Cideciyan, Alejandro J Roman, Raymond L Warner, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 24, 2008
Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kineticsArtur V Cideciyan, Tomas S Aleman, Sanford L Boye, et al.
Lancet (London, England)|September 7, 2024
Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation studyPaul Yang, Laura P Pardon, Allen C Ho, et al.
Human Gene Therapy|September 1, 2006
Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosisSamuel G Jacobson, Sanford L Boye, Tomas S Aleman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 29, 2006
Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injectionSamuel G Jacobson, Gregory M Acland, Gustavo D Aguirre, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Human Molecular Genetics|May 9, 2008
Usher syndromes due to MYO7A, PCDH15, USH2A or GPR98 mutations share retinal disease mechanismSamuel G Jacobson, Artur V Cideciyan, Tomas S Aleman, et al.
Investigative Ophthalmology & Visual Science|July 7, 2009
CERKL mutations cause an autosomal recessive cone-rod dystrophy with inner retinopathyTomas S Aleman, Nagasamy Soumittra, Artur V Cideciyan, et al.
Iscience|May 17, 2021
Safety and improved efficacy signals following gene therapy in childhood blindness caused by <i>GUCY2D</i> mutationsSamuel G Jacobson, Artur V Cideciyan, Allen C Ho, et al.
Iscience|October 24, 2022
Night vision restored in days after decades of congenital blindnessSamuel G Jacobson, Artur V Cideciyan, Allen C Ho, et al.
Investigative Ophthalmology & Visual Science|July 16, 2011
Human CRB1-associated retinal degeneration: comparison with the rd8 Crb1-mutant mouse modelTomas S Aleman, Artur V Cideciyan, Geoffrey K Aguirre, et al.
International Journal of Molecular Sciences|October 16, 2024
Evaluation of Retinal Structure and Visual Function in Blue Cone Monochromacy to Develop Clinical Endpoints for L-opsin Gene TherapyArtur V Cideciyan, Alejandro J Roman, Raymond L Warner, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 24, 2008
Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kineticsArtur V Cideciyan, Tomas S Aleman, Sanford L Boye, et al.
Lancet (London, England)|September 7, 2024
Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation studyPaul Yang, Laura P Pardon, Allen C Ho, et al.
Human Gene Therapy|September 1, 2006
Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosisSamuel G Jacobson, Sanford L Boye, Tomas S Aleman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 29, 2006
Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injectionSamuel G Jacobson, Gregory M Acland, Gustavo D Aguirre, et al.
Pageof 10